HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OABI
OmniAb, Inc.
There isn't enough reported data to score OABI yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OABI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Healthy | |
| Unavailable |
OABI's revenue and cash flow are currently healthy, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OABI PE Valuation
OABI has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OABI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OABI's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
OABI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.34 | +$0.25 |
| Q2 2026 | -$0.36 | +$0.25 |
| Q1 2026 | -$0.46 | +$0.13 |
| Q4 2025 | -$0.57 | +$0.04 |
| Q3 2025 | -$0.59 | +$0.03 |
| Q2 2025 | -$0.61 | +$0.01 |
| Q1 2025 | -$0.59 | +$0.05 |
| Q4 2024 | -$0.61 | -$0.10 |
OABI has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OABI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over OABI on profitability, with a higher operating margin.
OABI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | +78% |
| Q2 2026 | $13.4M | +244% |
| Q1 2026 | $14.4M | +247% |
| Q4 2025 | $8.4M | -22% |
| Q3 2025 | $2.2M | -46% |
| Q2 2025 | $3.9M | -49% |
| Q1 2025 | $4.2M | +9.3% |
| Q4 2024 | $10.8M | +124% |
OABI's revenue is recovering but still below its 2023 peak: $4M last quarter, up 78% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -410% | +400 points |
| Q2 2026 | -49% | +367 points |
| Q1 2026 | -54% | +399 points |
| Q4 2025 | -188% | -41 points |
| Q3 2025 | -810% | -336 points |
| Q2 2025 | -416% | -202 points |
| Q1 2025 | -454% | +140 points |
| Q4 2024 | -147% | +293 points |
OABI's operating margin was โ410% last quarter, up 400 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OABI on cash flow, with more consistent year-over-year improvement.
OABI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +$20.5M |
| Q2 2026 | $2.6M | +$7.9M |
| Q1 2026 | -$5.1M | +$11M |
| Q4 2025 | -$5.7M | -$1.8M |
| Q3 2025 | -$9.9M | -$3.2M |
| Q2 2025 | -$5.3M | +$7.6M |
| Q1 2025 | -$16.1M | +$1.9M |
| Q4 2024 | -$3.9M | +$5.3M |
OABI's free cash flow has turned positive after three years mostly in the red: $2M over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OABI Net Leverage
OABI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OABI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 86.4 | Overbought |
OABI's weekly RSI is 71 (overbought) and its Stochastic is 86 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
HIMS has no meaningful PE right now: it lost money over the past year.
OABI PE vs Healthcare Sector
OABI has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OABI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.83 | 2.5% above |
| 20 week MA | $3.88 | 28% above |
| 50 week MA | $2.70 | 83% above |
| 100 week MA | $2.45 | 102% above |
| 200 week MA | $3.54 | 40% above |
OABI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to โ56% in 2021. It's down 42% so far in 2026.
OABI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $6.61 | $3.56 | -46% |
| 2023 | $3.56 | $6.17 | +73% |
| 2024 | $6.17 | $3.59 | -42% |
| 2025 | $3.59 | $1.93 | -46% |
| 2026 YTD | $1.93 | $4.95 | +156% |
OABI has the edge over HIMS on returns for 2026, with the stronger performance.